ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
CheckMate-067: Raising the Bar for the Next Decade in Oncology.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Article
- Small molecules targeting the PD-1/PD-L1 axis for cancer immunotherapy.Theranostics · 2026Review
- Tumor immunology: unraveling the complex interaction between tumors and the immune system: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Immune checkpoint inhibitor-induced pancreatic enzyme elevation in melanoma patients: Incidence, management and therapy-A multicentre analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Soluble CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA-4 in melanoma.EMBO molecular medicine · 2025Article
- Exploring Motives Behind Ideal Melanoma Survivorship Care Plans With Multiple Stakeholders: A Cocreation Study.JMIR cancer · 2025Article
- Pain Related Quality of Life in Neurofibromatosis Type 1: A Narrative Review.Current pain and headache reports · 2024Review
- Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment.Journal of clinical medicine · 2024Article
- Long-Term Survival in Patients With Advanced Melanoma.JAMA network open · 2024Article
- Article
- Clinical and translational attributes of immune-related adverse events.Nature cancer · 2024Review
- Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications.Frontiers in immunology · 2024Review
- Immunotherapy in melanoma: advances, pitfalls, and future perspectives.Frontiers in molecular biosciences · 2024Review
- CheckMate-915: does adjuvant CTLA-4 blockade play a role in resected melanoma?Annals of translational medicine · 2023Article
- Precision targeted therapy for EGFR mutation-positive NSCLC: Dilemmas and coping strategies.Thoracic cancer · 2023Review
- Oncological healthcare providers' perspectives on appropriate melanoma survivorship care: a qualitative focus group study.BMC cancer · 2023Article
- Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis.Therapeutic advances in medical oncology · 2023Article
- Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients.Frontiers in oncology · 2023Article
- Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma.The British journal of dermatology · 2022Article
- Reply to T. Olivier et al.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.